🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 29 of 55

  1. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  2. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  3. LENVIMA 4 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    advanced stage hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  4. LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  5. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  6. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  7. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  8. LEVOFOLINATE DE CALCIUM ZENTIVA 10 mg/ml, solution injectable (IM/IV), Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Bemarituzumab, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ACCORD 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  9. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  10. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  11. LIBTAYO 350 mg concentrate for solution for infusion., Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  12. LIBTAYO 350 mg concentrate for solution for infusion., IMUNOCARE 5% crema

    The George Institute

    Cutaneous Basal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597

    Lacuna Pharma Pty Ltd

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  14. LIBTAYO 350 mg concentrate for solution for infusion., M1774, M1774, M1774

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. LIBTAYO 350 mg concentrate for solution for infusion., THIO

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  17. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. LM-302

    LaNova Medicines Limited

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  19. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  20. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  21. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  22. LN-145

    Iovance Biotherapeutics B.V.

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial

  23. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  24. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial

  25. LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1

    Disc Medicine

    B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma

    phase 2 small molecule active

    1 trial

  26. LUMYKRAS 120 mg film-coated tablets, LUMYKRAS 240 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  27. LY2157299

    Eli Lilly and Company

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

  28. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  29. Lacutamab

    Lacuna Pharma Pty Ltd

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  30. Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  31. Lapatinib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  32. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  33. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  34. Lenalidomide

    United Therapeutics Europe Ltd

    Recurrent Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  35. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  36. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

  37. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  38. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  39. Lenvatinib

    United Therapeutics Europe Ltd

    Columnar Cell Variant Thyroid Gland Papillary Carcinoma

    phase 2 small molecule completed

    1 trial

  40. Lenvatinib

    The First People's Hospital of Lianyungang

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  41. Lenvatinib

    Eisai Co.,

    Osteosarcoma

    phase 2 small molecule completed

    1 trial

  42. Lenvatinib, Belzutifan, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Patients with localized renal cell carcinoma

    phase 2 small molecule active

    1 trial

  43. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    The George Institute

    Resectable mucosal melanomas

    phase 2 small molecule active

    1 trial

  44. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, MK-1308A

    Merck Sharp and Dohme

    Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive

    phase 2 small molecule active

    1 trial

  45. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion., Lenvatinib

    Fondazione Telethon ETS

    vulvar cancer

    phase 2 small molecule active

    1 trial

  46. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 small molecule active

    1 trial

  47. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830, ETOPOSIDE, Lenvatinib, CISPLATIN, boserolimab, CARBOPLATIN

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  48. Lenvatinib, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.